Hemostatic composition

• US 20030224056A1
• Filed: 05/31/2002
• Published: 12/04/2003
• Est. Priority Date: 05/31/2002
• Status: Active Grant

• Current Assignee: Materials Modification Inc.
• Original Assignee: Materials Modification Inc.
• Inventors: Kotha, Sanjay, Sudarshan, Tirumalai S.
• Granted Patent: US 7,670,623 B2
• Time in Patent Office: Days
• US Class Current: 424/489
• CPC Class Codes: A61K 38/4833 Thrombin (3.4.21.5)
• CPC Class Codes: A61K 38/4846 Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
• CPC Class Codes: A61K 9/501 Inorganic compounds
• CPC Class Codes: A61K 9/5094 Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
• CPC Class Codes: A61L 24/02 containing inorganic materials
• CPC Class Codes: A61L 2400/04 Materials for stopping bleeding
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

A hemostatic composition includes a carrier medium including a predetermined amount of a particulate material. The particulate material is comprised of core particles with a coating. The core particles have an average particle size of about 5 nm to 10 μm, and the coating is one of gold, silica, silver, platinum, steel, cobalt, carbon, a polymer, or a combination thereof.

Claims

1. A hemostatic composition, comprising:

a) a carrier medium;

b) a predetermined amount of a particulate material in said medium;

c) said particulate material comprising core particles with a coating;

d) said core particles having an average particle size of about 5 nm to 10 μ

m; and

e) said coating comprising a member selected from the group consisting of gold, silica, silver, platinum, steel, cobalt, carbon, a polymer, procoagulant molecules, and a combination thereof.

2. The composition of claim 1, wherein:

a) said core particles comprise a member selected from the group consisting of iron, iron oxide, cobalt, cobalt oxide, nickel, nickel oxide, and an alloy or a combination thereof.

3. The composition of claim 1, wherein:

a) said core particles have an average particle size of about 10 nm to 1 μ

m.

4. The composition of claim 1, wherein:

a) said core particles have an average particle size of about 10 nm to 300 nm.

5. The composition of claim 1, wherein:

a) said core particles comprise a general shape selected from the group consisting of a sphere, a needle, a cube, an oval, irregular, a cylinder, a diamond, and a combination thereof.

6. The composition of claim 1, wherein:

a) said core particles comprise clusters.

7. The composition of claim 1, wherein:

a) said core particles comprise the general shape of blood platelets.

8. The composition of claim 1, wherein:

a) said polymer is selected from the group consisting of polyethylene glycol, dextran, Tween, sorbitol, mannitol, and a combination thereof.

9. The composition of claim 1, wherein:

a) said coating has a thickness of about 1 nm to 1 μ

m.

10. The composition of claim 1, wherein:

a) said coating has a thickness of about 5 nm to 50 nm.

11. The composition of claim 1, wherein:

a) said procoagulant molecules are selected from the group consisting of thrombin and Factor VII a.

12. The composition of claim 1, further comprising:

a) a surfactant or dispersant.

13. The composition of claim 1, wherein:

a) the concentration of said particulate material is about 0.1% to 70% (w/w) of the composition.

14. The composition of claim 1, wherein:

a) said particulate material is non-toxic to bio-cells or biomolecules.

15. The composition of claim 1, wherein:

a) said carrier is selected from the group consisting of water, saline solution, sugar solution, Lactose Ringers, and blood plasma.

16. The composition of claim 1, wherein:

a) said core particles have a narrow distribution of sizes.

17. A magnetic hemostatic fluid for controlling external or internal bleeding in a subject, comprising:

a) a carrier fluid;

b) a predetermined amount of a magnetic particulate material in said fluid;

c) said particulate material comprising core particles with a coating having a thickness of about 1 nm to 10 μ

m;

d) said core particles having an average particle size of about 5 nm to 10 μ

m;

e) said core particles comprising a member selected from the group consisting of iron, iron oxide, cobalt, cobalt oxide, nickel, nickel oxide, and an alloy or a combination thereof; and

f) said coating comprising a member selected from the group consisting of gold, silica, silver, platinum, steel, cobalt, carbon, a polymer, and a combination thereof.

18. The composition of claim 17, wherein:

a) said core particles have an average particle size of about 10 nm to 1 μ

m.

19. The composition of claim 17, wherein:

a) said core particles have an average particle size of about 10 nm to 300 nm.

20. The composition of claim 17, wherein:

a) said core particles comprise a general shape selected from the group consisting of a sphere, a needle, a cube, an oval, irregular, a cylinder, a diamond, and a combination thereof.

21. The composition of claim 17, wherein:

a) said core particles comprise clusters.

22. The composition of claim 17, wherein:

a) said core particles comprise the general shape of blood platelets.

23. The composition of claim 17, wherein:

a) said polymer is selected from the group consisting of polyethylene glycol, dextran, Tween, sorbitol, mannitol, and a combination thereof.

24. The composition of claim 17, wherein:

a) said coating has a thickness of about 5 nm to 50 nm.

25. The composition of claim 17, wherein:

a) said procoagulant molecules are selected from the group consisting of thrombin and Factor VII a.

26. The composition of claim 17, further comprising:

a) a surfactant or dispersant.

27. The composition of claim 17, wherein:

b) the concentration of said particulate material is about 0.1% to 70% (w/w) of the composition.

28. The composition of claim 17, wherein:

a) said particulate material is non-toxic to bio-cells or biomolecules.

29. The composition of claim 17, wherein:

b) said carrier is selected from the group consisting of water, saline solution, sugar solution, Lactose Ringers, and blood plasma.

30. The composition of claim 17, wherein:

a) said core particles have a narrow distribution of sizes.

31. The composition of claim 17, wherein:

a) the magnetic particles comprise paramagnetic or superparamagnetic particles.

32. A method of controlling bleeding in a subject in need thereof, comprising the steps of:

a) administering to a subject having internal or external bleeding a predetermined amount of a hemostatic fluid;

b) the hemostatic fluid, comprising;

i) a carrier medium;

ii) a predetermined amount of a particulate material in the medium;

iii) the particulate material comprising core particles with a coating;

iv) the core particles having an average particle size of about 5 nm to 10 μ

m; and

v) the coating comprising a member selected from the group consisting of gold, silica, silver, platinum, steel, cobalt, carbon, a polymer, procoagulant molecules, and a combination thereof;

c) applying a magnetic field adjacent the site of a lesion causing the bleeding so as to form a cluster of the particulate material for thereby preventing the flow of blood through the lesion.